Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia

Archives of Medical Research

Volumn 47, Issue 1, 2016, Pages 55-64

  Sandoval Borrego, Daniela ^a   Moreno Lafont, Martha C ^a   Vazquez Sanchez, Ernesto Antonio ^a   Gutierrez Hoya, Adriana ^b   López Santiago, Rubén ^a   Montiel Cervantes, Laura A ^a,c   Ramírez Saldaña, Maricela ^a   Vela Ojeda, Jorge ^a,c  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Acute myeloid leukemia (AML); Killer cell immunoglobulin like receptors (KIRs); Natural cytotoxicity receptors (NCRs); NK cell receptors; NK cells

Indexed keywords

CD158 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY C; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; NATURAL KILLER CELL RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; AUTOFLUORESCENCE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; ISOLATION AND PURIFICATION; MALE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; ACUTE MYELOID LEUKEMIA; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-12; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, NATURAL KILLER CELL;

EID: 84962018336     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2016.02.001     Document Type: Article

References (24)

1. Löwenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. N Engl J Med 1999, 341:1051-1062.
2. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103:620-625.
3. Montesinos J.J., Mayani H. Nuevos conceptos en la biología de la leucemia mieloide aguda. Gac Med Mex 2002, 138:67-76.
4. Paresh V., Frederick R.A., Charles C. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant 2015, 21:8-15.
5. Jones C.V., Copelan E.A. Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation. Future Oncol 2009, 5:559-568.
6. Stone R.M., O'Donnell M.R., Sekeres M.A. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004, 98-117.
7. Döhner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
8. Ahn Y., Weigel B., Verneris M.R. Killing the killer: natural killer cells to treat Ewing's sarcoma. Clin Cancer Res 2010, 16:3819-3821.
9. Cheent K., Khakoo S.I. Natural killer cells: integrating diversity with function. Immunology 2009, 126:449-457.
10. Bottino C., Moretta L., Moretta A. NK cell activating receptors and tumor recognition in humans. Curr Top Microbiol Immunol 2006, 298:175-182.
11. Agüera S.G., Boutet P., Reyburn H.T., et al. Brief residence at the plasma membrane of the MHC class I-related chain B is due to clathrin-mediated cholesterol-dependent endocytosis and shedding. J Immunol 2009, 182:4800-4808.
12. López C.L., Suárez B.A., López A.S., et al. The NKG2D receptor: sensing stressed cells. Trends Mol Med 2008, 14:179-189.
13. Bryceson Y.T., Chiang S.C., Darmanin S., et al. Molecular mechanisms of natural killer cell activation. J Innate Immun 2011, 3:216-226.
14. Coles S.J., Wang E.C., Darley R.L., et al. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 2011, 25:792-799.
15. Pérez R.M. Importancia de las moléculas KIR en el trasplante. Rev Mex Med Tran 2010, 3:S21-S23.
16. Rubnitz J.E., Gibson B., Smith F.O. Acute myeloid leukemia. Hematol Oncol Clin North Am 2010, 24:35-63.
17. Fregni G., Perier A., Avril M.F., et al. NK cells sense tumors, course of disease and treatments. Consequences for NK-based therapies. Oncoimmunology 2012, 1:38-47.
18. Malhotra A., Shanker A. NK cells: immune cross-talk and therapeutic implications. Immunotherapy 2011, 3:1143-1166.
19. Diermayr S., Himmelreich H., Durovic B., et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 2008, 111:1428-1436.
20. Ashiru O., Boutet P., Fernández M.L., et al. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA 008 that is shed by tumor cells in exosomes. Cancer Res 2010, 70:481-489.
21. Hilpert J., Grosse-Hovest L., Salih H.R., et al. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol 2012, 189:1360-1371.
22. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer. Suppression and promotion. Science 2011, 331:1565-1570.
23. Farnault L., Sanchez C., Baier C., et al. Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications. Clin Dev Immunol 2012, 2012:421702.
24. Feuchtinger T., Pfeiffer M., Lang P., et al. Cytolytic activity of NK cell clones against acute childhood precursor-B-cell leukaemia is influenced by HLA class I expression on blasts and the differential KIR phenotype of NK clones. Bone Marrow Transplant 2009, 43:875-881.